{"id":482757,"title":"Biologic drugs (Schedule D drugs) – Division 4 proposed regulatory amendments: Notice to stakeholders - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-06","captureTimestamp":"2026-01-06T19:51:30.046000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/programs/consultation-proposed-agile-regulations-guidance-licensing-drugs-medical-devices/biologic-drugs-schedule-d-division-4-proposed-regulatory-amendments-notice.html?wbdisable=true","snippet":"Biologic drugs (Schedule D drugs) – Division 4 proposed regulatory amendments: Notice to stakeholders A public consultation on proposed amendments to modify Division 4 in Part C of the Food and Drug Regulations (FDR) for biologic drugs was held from December 2022 to April 2023. A…","rawSnapshotUrl":"/api/snapshots/raw/482757","browseUrl":"https://replay.healtharchive.ca/job-6/20260106195130/https://www.canada.ca/en/health-canada/programs/consultation-proposed-agile-regulations-guidance-licensing-drugs-medical-devices/biologic-drugs-schedule-d-division-4-proposed-regulatory-amendments-notice.html?wbdisable=true#ha_snapshot=482757","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}